Ibrahim, Sherrif F.Kasprzak, Julia M.Hall, Mary A.Fitzgerald, Alison L.Siegel, Jennifer J.Kurley, Sarah J.Covington, Kyle R.Goldberg, Matthew S.Farberg, Aaron S.Trotter, Shannon C.Reed, KennethBrodland, David G.Koyfman, Shlomo A.Somani, Ally-KhanArron, Sarah T.Wysong, Ashley2023-02-102023-02-102022-03Ibrahim, S. F., Kasprzak, J. M., Hall, M. A., Fitzgerald, A. L., Siegel, J. J., Kurley, S. J., Covington, K. R., Goldberg, M. S., Farberg, A. S., Trotter, S. C., Reed, K., Brodland, D. G., Koyfman, S. A., Somani, A.-K., Arron, S. T., & Wysong, A. (2022). Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology (London, England), 18(7), 833–847. https://doi.org/10.2217/fon-2021-1277https://hdl.handle.net/1805/31219Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan–Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for Class 1 and ≥50% for Class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalclinicopathologic risk factorscutaneous squamous cell carcinomagene expression profileArticle